Abstract | PURPOSE: The taxanes have demonstrated activity as radiation sensitizers in preclinical studies. This study was designed to determine the maximum-tolerated dose (MTD), optimal schedule, and toxicities of docetaxel in combination with concomitant standard chest radiotherapy. PATIENTS AND METHODS: Twenty-nine patients with advanced non-small-cell lung or esophageal cancer enrolled in this phase I study to evaluate escalating docetaxel doses at three schedules. Docetaxel was administered as two 21-day cycles at doses of 40, 60, and 75 mg/m2 per cycle. Docetaxel administration schedules were as follows: schedule A, once every 3 weeks; schedule B, 2 of 3 weeks; or schedule C, weekly. Six weeks of concomitant standard chest radiotherapy in 1.8- to 2.0-Gy daily fractions was delivered to 60 Gy total. RESULTS: CONCLUSION:
|
Authors | A M Mauer, G A Masters, D J Haraf, P C Hoffman, S M Watson, H M Golomb, E E Vokes |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 16
Issue 1
Pg. 159-64
(Jan 1998)
ISSN: 0732-183X [Print] United States |
PMID | 9440738
(Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antineoplastic Agents, Phytogenic
- Taxoids
- Docetaxel
- Paclitaxel
|
Topics |
- Adult
- Aged
- Antineoplastic Agents, Phytogenic
(administration & dosage, adverse effects)
- Bone Marrow
(drug effects, radiation effects)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, pathology, radiotherapy)
- Combined Modality Therapy
- Docetaxel
- Drug Administration Schedule
- Esophageal Neoplasms
(drug therapy, pathology, radiotherapy)
- Esophagitis
(etiology)
- Female
- Humans
- Lung Neoplasms
(drug therapy, pathology, radiotherapy)
- Male
- Middle Aged
- Paclitaxel
(administration & dosage, adverse effects, analogs & derivatives)
- Radiotherapy Dosage
- Taxoids
- Treatment Outcome
|